The most valuable pharmaceutical brand TOP25, 2 Chinese companies on the list!
In the past few months, pharmaceutical and biotechnology companies have become the focus. Dozens of companies around the world are developing drugs and vaccines against COVID-19. In fact, the share prices of some pharmaceutical companies have doubled in just a few months. Fan.
However, not all companies in the pharmaceutical industry have a very valuable brand. Which pharmaceutical companies' brands have entered the relevant ranking list this year. Today I share with you a top 25 pharmaceutical brand.
Friends who follow MRCLUB should note that British brand consulting companies evaluate more than 5,000 global brands every year. The following ranking is Brand Finance's list of the top 25 pharmaceutical brands this year.


The top-ranked Johnson & Johnson company has seen its brand value drop by 11% since last year, but according to Richard Haigh, Managing Director of Brand Finance, Johnson & Johnson is expected to maintain its leading position in the industry in the next few years, thanks to the company’s research and development In terms of continuous investment, the company's latest investment is the development of a covid-19 vaccine.
Roche continued to grow, with a 10% growth rate last year to bring the brand value to 7.6 billion US dollars, ranking second in the list.
It is also worth mentioning that in addition to determining the overall brand value, Brand Finance also uses a balanced scorecard to assess the relative strength of the brand from three indicators: market investment, stakeholder rights and business performance. This is called the brand strength index ( BSI), according to the report of Brand Finance, according to this standard, Roche is now the most powerful brand in the industry, with a brand strength index (BSI) score of 79.7 points, and the only brand in the ranking with an AAA rating.
According to the Brand Strength Index (BSI), the top five most powerful pharmaceutical brands in the world are Roche, Bayer, Bristol-Myers Squibb, Johnson & Johnson, Novo Nordisk.

Asian pharmaceutical brands enter the rankings for the first time
This year Brand Finance expanded its ranking from the top 10 to the top 25, and Asian pharmaceutical brands also appeared in the rankings for the first time. They are Sinopharm Group from China, Shanghai Pharmaceuticals and Takeda Pharmaceuticals headquartered in Japan. Sinopharm Group and Takeda Pharmaceuticals each have their own The brand value of USD 2 billion ranked 15th and 16th respectively, and Shanghai Pharmaceuticals ranked 24th.
Brand Finance believes that as a symbol of the rapid development of China's medical device industry, Sinopharm Group has acquired a 60% stake in China's scientific equipment company, integrated medical device distribution business, and expanded its influence in the industry.
Takeda Pharmaceutical, which ranked 16th, followed closely after the acquisition of Shire at the beginning of last year, quickly reshaping its brand, increasing its exposure in the United States, the world’s largest pharmaceutical market, and adding Shire’s lucrative drug portfolio to Takeda's product pipeline.
Moreover, Takeda Pharmaceuticals is now listed on the Tokyo and New York Stock Exchanges, and it can expand its global business through wider capital market access and providing longer trading time for global investors.
2026-09-30
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
South Korea to Impose Anti-Dumping Duties on Caustic Soda: Chinese Mainland Firms Face Up to 22.21%, Taiwan Region 38.89%
-
EAEU Initiates Review of Anti-Dumping Measures on Chinese Titanium Dioxide, Suspends Duties During Investigation
-
Three Major Indian Chemical Investments Target China's PC Exports
-
Pakistan Launches Successive Anti-dumping Investigations against Chinese Products, Involving Soda Ash, Ibuprofen and Other Raw Materials
-
South Korea Initiates Anti-Dumping Probe on Chinese PVC Suspension Resin, Involving Tianjin Bohua and Wanhua Chemical
-
China Keeps Registering Pesticides
-
India Launches Anti-Dumping Probe into PET Film from China, Singapore, Thailand and the UAE
-
INEOS Warns Chinese Chemical “Dumping” Is Hitting Europe’s Industry
-
Covestro Builds New 660,000-ton MDI Plant in China: Global Supply Gap Meets Chinese Overcapacity Head-On
-
India Imposes Final Anti‑Dumping Duties on Ethylenediamine from China, EU, Saudi Arabia, and Taiwan, China, with Top Rate of $575/tonne
Recommend Reading
-
BASF’s €8.7 Billion Zhanjiang Verbund Site Fully Operational
-
Shell Polymers Explosion Caused About $95 Million in Damage, U.S. CSB Finds
-
Wanhua Chemical Establishes a RMB 1.488 Billion New Energy Materials Company in Weifang, Further Integrating Green Power and Battery Materials Businesses
-
Ineos Rescues UK's Last Dichloroethane Plant
-
Kering and L'Oréal Form $4 Billion Strategic Alliance in Luxury Beauty and Wellness
-
Remote Raw Material Boost, PC Prices Recover After Falling in the First Half of July in China
-
Business Society September 20, 2026 DOP Trend Analysis: Clearly Downward
-
Business Society’s PVC Market Outlook on September 3, 2026: Relatively Strong Fluctuations
-
DMF Market Primarily Operates Strongly
-
Cost-side Speculative Sentiment Rises, PP Strongly Rebounds in Early July